Drugs最新文献_第9页

Capivasertib: First Approval. Capivasertib：首次批准。

IF 11.5 1区医学

Drugs Pub Date : 2024-03-01 DOI: 10.1007/s40265-024-01998-6

Matt Shirley

引用次数: 0

Correction: Zilucoplan: First Approval. 更正：Zilucoplan：首次批准。

IF 11.5 1区医学

Drugs Pub Date : 2024-03-01 Epub Date: 2024-03-19 DOI: 10.1007/s40265-024-02019-2

Matt Shirley

引用次数: 0

Nirogacestat: First Approval. 尼罗加司他首次批准。

IF 11.5 1区医学

Drugs Pub Date : 2024-03-01 DOI: 10.1007/s40265-024-02002-x

Susan J Keam

引用次数: 0

Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability. 多发性硬化症的 CD20 靶向药物：药理学、疗效、安全性和耐受性。

IF 11.5 1区医学

Drugs Pub Date : 2024-03-01 Epub Date: 2024-03-14 DOI: 10.1007/s40265-024-02011-w

Alise K Carlson, Moein Amin, Jeffrey A Cohen

{"title":"Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability.","authors":"Alise K Carlson, Moein Amin, Jeffrey A Cohen","doi":"10.1007/s40265-024-02011-w","DOIUrl":"10.1007/s40265-024-02011-w","url":null,"abstract":"Currently, there are four monoclonal antibodies (mAbs) that target the cluster of differentiation (CD) 20 receptor available to treat multiple sclerosis (MS): rituximab, ocrelizumab, ofatumumab, and ublituximab. B-cell depletion therapy has changed the therapeutic landscape of MS through robust efficacy on clinical manifestations and MRI lesion activity, and the currently available anti-CD20 mAb therapies for use in MS are a cornerstone of highly effective disease-modifying treatment. Ocrelizumab is currently the only therapy with regulatory approval for primary progressive MS. There are currently few data regarding the relative efficacy of these therapies, though several clinical trials are ongoing. Safety concerns applicable to this class of therapeutics relate primarily to immunogenicity and mechanism of action, and include infusion-related or injection-related reactions, development of hypogammaglobulinemia (leading to increased infection and malignancy risk), and decreased vaccine response. Exploration of alternative dose/dosing schedules might be an effective strategy for mitigating these risks. Future development of biosimilar medications might make these therapies more readily available. Although anti-CD20 mAb therapies have led to significant improvements in disease outcomes, CNS-penetrant therapies are still needed to more effectively address the compartmentalized inflammation thought to play an important role in disability progression.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10982103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lebrikizumab: First Approval. Lebrikizumab：首次批准。

IF 11.5 1区医学

Drugs Pub Date : 2024-03-01 DOI: 10.1007/s40265-024-02000-z

Susan J Keam

引用次数: 0

Berdazimer Topical Gel, 10.3%: First Approval. Berdazimer 外用凝胶，10.3%：首次批准。

IF 11.5 1区医学

Drugs Pub Date : 2024-03-01 DOI: 10.1007/s40265-024-02012-9

Susan J Keam

引用次数: 0

Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1. 更正：卢马西兰：原发性高草酸尿症 1 型综述。

IF 11.5 1区医学

Drugs Pub Date : 2024-03-01 Epub Date: 2024-03-15 DOI: 10.1007/s40265-024-02014-7

Connie Kang

引用次数: 0

Vonoprazan: A Review in Helicobacter pylori Infection. 沃诺普拉赞：幽门螺杆菌感染综述

IF 11.5 1区医学

Drugs Pub Date : 2024-03-01 Epub Date: 2024-02-23 DOI: 10.1007/s40265-023-01991-5

Matt Shirley

{"title":"Vonoprazan: A Review in Helicobacter pylori Infection.","authors":"Matt Shirley","doi":"10.1007/s40265-023-01991-5","DOIUrl":"10.1007/s40265-023-01991-5","url":null,"abstract":"Treatment for the eradication of Helicobacter pylori infection, a leading cause of peptic ulcer disease and an important risk factor for gastric cancer and mucosa-associated lymphoid tissue lymphoma, is indicated whenever infection is identified. However, treatment success rates with current guideline-recommended proton-pump inhibitor (PPI)-based regimens remain suboptimal, with one potential factor associated with treatment failure being inadequate acid suppression. Vonoprazan (Voquezna®) is a first-in-class potassium-competitive acid blocker with the potential to provide potent and sustained acid suppression. Following clinical trials conducted mainly in Asia (supported by post-marketing experience from Asia) and the phase III PHALCON-HP trial conducted in the USA and Europe, vonoprazan is now approved in the USA for use in combination with amoxicillin (dual therapy) or amoxicillin and clarithromycin (triple therapy) for the treatment of H. pylori infection in adults. The vonoprazan-based dual and triple therapy regimens were generally well tolerated in PHALCON-HP. In addition, vonoprazan has advantages including a rapid onset of action and no food effect, making vonoprazan-based dual and triple therapy regimens valuable alternatives to standard PPI-based triple therapy in the treatment of H. pylori infection.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139930470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape. 微胶囊过氧化苯甲酰治疗酒渣鼻的背景：当前治疗形势回顾。

IF 11.5 1区医学

Drugs Pub Date : 2024-03-01 Epub Date: 2024-02-29 DOI: 10.1007/s40265-024-02003-w

Seemal R Desai, Hilary Baldwin, James Q Del Rosso, Richard L Gallo, Neal Bhatia, Julie C Harper, Jean Philippe York, Linda Stein Gold

{"title":"Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape.","authors":"Seemal R Desai, Hilary Baldwin, James Q Del Rosso, Richard L Gallo, Neal Bhatia, Julie C Harper, Jean Philippe York, Linda Stein Gold","doi":"10.1007/s40265-024-02003-w","DOIUrl":"10.1007/s40265-024-02003-w","url":null,"abstract":"Rosacea, a chronic skin condition affecting millions of people in the USA, leads to significant social and professional stigmatization. Effective management strategies are crucial to alleviate symptoms and improve patients' quality of life. Encapsulated benzoyl peroxide 5% (E-BPO 5%) is a newly FDA-approved topical treatment for rosacea that shows promise in enhancing therapeutic response and minimizing skin irritation. This review aims to assess the role of recently FDA approved E-BPO 5% in the current treatment landscape for rosacea management, as it is not yet included in clinical guidelines that predominantly rely on older approved therapies. The review focuses on randomized controlled trials conducted in English-speaking adults. It evaluates the efficacy, safety, and tolerability of various US Food and Drug Administration (FDA)-approved agents used for rosacea treatment, including E-BPO cream, metronidazole gel, azelaic acid gel and foam, ivermectin cream, minocycline foam, oral doxycycline, brimonidine gel, and oxymetazoline HCl cream. Existing therapies have been effective in reducing papulopustular lesions and erythema associated with rosacea for many years. E-BPO 5% offers a promising addition to the treatment options due to its microencapsulation technology, which prolongs drug delivery time and aims to improve therapeutic response while minimizing skin irritation. Further research is necessary to determine the exact role of E-BPO 5% in the therapeutic landscape for rosacea. However, based on available evidence, E-BPO 5% shows potential as a valuable treatment option for managing inflammatory lesions of rosacea, and it may offer benefits to patients including: rapid onset of action, demonstrated efficacy by Week 2, excellent tolerability, and sustained long-term results for up to 52 weeks of treatment.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10982091/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SER-109 (VOWST^™): A Review in the Prevention of Recurrent Clostridioides difficile Infection. ser-109 (vowst™)：预防复发性艰难梭菌感染的综述。

IF 11.5 1区医学

Drugs Pub Date : 2024-03-01 Epub Date: 2024-03-05 DOI: 10.1007/s40265-024-02006-7

Hannah A Blair

{"title":"SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection.","authors":"Hannah A Blair","doi":"10.1007/s40265-024-02006-7","DOIUrl":"10.1007/s40265-024-02006-7","url":null,"abstract":"SER-109 (VOWST™; fecal microbiota spores, live-brpk) is a live biotherapeutic product indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in patients 18 years of age and older following standard of care (SOC) antibacterial treatment for recurrent CDI. It is a purified bacterial spore suspension sourced from healthy donors. As the first oral faecal microbiota product approved for prevention of recurrent CDI, SER-109 is administered as four capsules once daily for three consecutive days. In a well-designed, placebo-controlled, phase III trial (ECOSPOR III), SER-109 significantly reduced the risk of recurrent CDI at 8 weeks post-treatment, with a durable response seen at 6 months post-treatment. Treatment with SER-109 was also associated with rapid and steady improvement in health-related quality of life compared with placebo. SER-109 was generally well tolerated, with a safety profile similar to that of placebo. The most common adverse events were of mild to moderate severity and generally gastrointestinal in nature. Thus, with the convenience of oral administration and lack of necessity for cold storage, SER-109 is a valuable option for preventing further CDI recurrence in adults following antibacterial treatment for recurrent CDI.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":null,"pages":null},"PeriodicalIF":11.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0